

Third Quarter 2026 Earnings

EARNINGS PRESENTATION

October 28, 2026

Forward Looking Statements and Non-GAAP Financial Measures

FORWARD-LOOKING STATEMENTS

Statements in this presentation that are not strictly historical, including statements regarding anticipated financial results, global and regional economic conditions, industry trends, geopolitical events, anticipated product introductions, future acquisitions, impact of trade and spending policies, impact of geopolitical conflict, the ability to execute the planned strategies, interest rate and current exchange rate impact, future prospects, shareholder value, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” “target”, or “will” or other words of similar meaning, are “forward-looking statements” within the meaning of the United States federal securities laws. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: deterioration of or instability in the economy, the markets we serve, international trade policies and deteriorating trade relations with other countries, including imposition of tariffs and retaliatory tariffs between United States and China and other countries, responsive economic nationalism, trade restrictions, and enhanced regulation, impact of any prolonged government shutdown, the financial markets, geopolitical conditions and conflicts including in the Middle East and in Ukraine, security breaches, data exfiltration, or other disruptions of our information technology systems, supply chain constraints, our ability to adjust purchases and manufacturing capacity to reflect market conditions, impact of development, deployment, and use of artificial intelligence, reliance on sole sources of supply, contractions or lower growth rates and cyclicity of markets we serve, competition, changes in industry standards and governmental regulations, our ability to recruit and retain key employees, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions or otherwise effectively deploy our capital, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, geopolitical, including war and sanctions, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, adverse effects of restructuring activities, risk related to tax treatment of our prior separations, impact of our indemnification obligation to Ralliant and Vontier, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters and climate change. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the subsequent quarters. These forward-looking statements speak only as of the date of this presentation, and Fortive does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

NON-GAAP FINANCIAL MEASURES

This presentation contains references to financial measures not presented in accordance with generally accepted accounting principles (“GAAP”). We have not reconciled forward-looking targets or outlook regarding non-GAAP measures because any corresponding GAAP measures and the reconciliations thereto would require us to make estimates or assumptions with precision about acquisitions, currency transactions, capital and other expenditures and similar adjustments during the relevant period. Information required by Regulation G with respect to historical non-GAAP financial measures are set forth in the appendix to this presentation and the “Investors” section of our website, www.fortive.com, under the heading “Financial Results”.

PRECISION TECHNOLOGIES SEPARATION

On June 28, 2025, the Company completed the separation (the “Separation”) of its former Precision Technologies (“PT”) segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation (“Ralliant”), the entity incorporated to hold the PT businesses. The accounting requirements for reporting Ralliant as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying financial information for all periods presented reflect this business as a discontinued operation. Unless otherwise indicated, all references in this report refer to continuing operations.

All growth or period changes refer to year-over-year comparisons unless otherwise stated. Forward looking financial information not otherwise presented as a range reflect assumptions underlying the midpoint of our forward-looking targets.

Key Messages



1

Strong Q3 financial performance and execution by Fortive team, delivering +7.2% core growth, ~10% adjusted EBITDA growth and ~13% adjusted EPS growth

2

Deployed ~\$300 million to share repurchases in Q3, bringing total share repurchases since the launch of new Fortive to ~\$2.3 billion, consistent with our disciplined capital allocation approach

3

Fortive *Accelerated* strategy contributing to growth acceleration, reinforcing confidence in medium-term financial framework and value creation opportunity

4

Raising FY 2026 adjusted EPS guidance to \$3.10 to \$3.14, up ~15% year-over-year at the midpoint, reflecting strong year-to-date performance and confidence in the trajectory of the business

Fortive *Accelerated* Strategy

1

Faster Profitable Organic Growth

- Innovation Acceleration
- Commercial Acceleration
- Recurring Customer Value

Powered by FBS Amplified

Recent new product introductions and commercial investments translating into core growth acceleration; continued strength in recurring revenue growth

2

Disciplined Capital Allocation

- Invest in organic growth
- Smaller bolt-on M&A
- Share repurchases
- Modest growing dividend

Deployed ~\$2.3 billion to share repurchases since launch of new Fortive, representing ~43 million shares or ~13% of diluted shares outstanding¹

Revamped bolt-on M&A engine in place, executing on opportunities that meet rigorous strategic and financial criteria

3

Build and Maintain Investor Trust

- Clear expectations and consistent delivery
- Simplified guidance and disclosure
- Do what we say we will do

Revamped internal financial processes for better forecast accuracy

Redesigned investor messaging and guidance framework

Delivered solid performance in every quarter since the July 2025 launch of new Fortive

Demonstrated progress

Ambition: 3-5 Year Total Shareholder Return > the S&P 500 Index²

Fortive Results

Q3 2026

	Q3 2026
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$1,107.5M +7.8% +7.2%
Adj. Gross Profit <i>Adj. Gross Profit Growth (YoY)</i> <i>Adj. Gross Margin</i>	\$692.6M +6.5% 62.5%
Adj. EBITDA <i>Adj. EBITDA Growth (YoY)</i> <i>Adj. EBITDA Margin</i>	\$338.8M +9.5% 30.6%
Adj. EPS <i>Adj. EPS Growth (YoY)</i>	\$0.77 13.2%
Trailing Twelve Month (TTM) Free Cash Flow <i>TTM FCF Conversion on Adj. Net Income</i>	\$1,062.0 +109.5%

COMMENTARY

- Core revenue growth of +7.2%, led by strong performance in IOS segment
- Adj. Gross Margin of 62.5%, down ~80 bps year-over-year, driven primarily by product mix, partially offset by operating leverage
- Adj. EBITDA grew ~10% year-over-year, reflecting adjusted gross profit growth, operating leverage and discrete structural cost savings, partially offset by growth investments; Adj. EBITDA margin expanded ~50 bps to 30.6%
- Adj. EPS grew ~13% year-over-year, driven by Adj. EBITDA growth and favorable impact of share repurchases, partially offset by higher interest and tax expense
- TTM Free Cash Flow Conversion on Adj. Net Income >100%

Intelligent Operating Solutions

Q3 2026

	Q3 2026
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$767.1M +9.8% +9.1%
Adj. Gross Profit <i>Adj. Gross Profit Growth (YoY)</i> <i>Adj. Gross Margin</i>	\$496.9M +8.3% 64.8%
Adj. EBITDA <i>Adj. EBITDA Growth (YoY)</i> <i>Adj. EBITDA Margin</i>	\$274.7M +13.6% 35.8%

COMMENTARY

- Core revenue growth of +9.1%, driven by acceleration in professional instrumentation, Facilities and Asset Lifecycle solutions and gas detection
- Adj. Gross Margin of ~65%, similar to Q2, and down ~90 bps year-over-year, driven primarily by product mix, partially offset by operating leverage
- Adj. EBITDA grew ~14%, driven by adjusted gross profit growth, operating leverage and discrete structural cost savings, partially offset by growth investments
- Adj. EBITDA margin expanded by ~120 basis points year-over-year to ~36%

Advanced Healthcare Solutions

Q3 2026

	Q3 2026
Revenue <i>Reported Growth</i> <i>Core Growth</i>	\$340.4M +3.7% +3.1%
Adj. Gross Profit <i>Adj. Gross Profit Growth (YoY)</i> <i>Adj. Gross Margin</i>	\$195.7M +2.1% 57.5%
Adj. EBITDA <i>Adj. EBITDA Growth (YoY)</i> <i>Adj. EBITDA Margin</i>	\$87.9M (4.8)% 25.8%

COMMENTARY

- Core revenue growth of +3.1%, driven by solid demand for healthcare consumables and SaaS offerings, with modest growth in capital equipment
- Adj. Gross Margin of ~58%, down about 90 bps year-over-year, driven primarily by product mix, partially offset by operating leverage
- Adj. EBITDA Margin of ~26%, ~flat sequentially and down YoY, driven by growth investments and the year-over-year headwind from discrete cost benefits in Q3'25, partially offset by operating leverage

Balance Sheet & Capital Allocation

Q3 2026

Balance Sheet

As of October 2, 2026

Cash and equivalents	\$0.38B
Gross Debt, principal amounts	\$3.53B
Net Debt	\$3.15B

Leverage

Q3 2026 TTM Adj. EBITDA	\$1.33B
Gross Debt / Adj. EBITDA	~2.6X
Net Debt / Adj. EBITDA	~2.4X

Cash Flow

TTM as of
October 2, 2026

TTM Operating Cash Flow	\$1,176.6M
TTM Capital Expenditures	(\$114.6M)
TTM Free Cash Flow	\$1,062.0M
<i>TTM Free Cash Conversion on Adj. Net Income</i>	<i>109.5%</i>

COMMENTARY & CAPITAL ALLOCATION HIGHLIGHTS

- Deployed ~\$300 million towards share repurchase in Q3, representing ~5M shares, at an average price of \$60.14
- Increased regular quarterly dividend by ~17% year-over-year in Q3
- Reduced leverage to 2.6x Gross Debt / Adjusted EBITDA
- Robust Free Cash Flow generation provides further capacity and flexibility to execute our capital deployment priorities, always with a disciplined focus on allocating capital to optimize shareholder returns over the medium to long term

Raising FY 2026 Guidance

Adj. EPS | FY 2026

\$3.10 to \$3.14



Fortive *Accelerated*

Innovating essential
technologies to keep our
world **safe** and **productive**



Appendix & Supplemental Reconciliation Data

CORE REVENUE GROWTH AND REVENUE BY GEOGRAPHY

	Three Months Ended October 2, 2026		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Total revenue growth (GAAP)	9.8 %	3.7 %	7.8 %
Excluding impact of:			
Acquisitions and divestitures	(0.4)%	(0.5)%	(0.5)%
Currency exchange rates	(0.3)%	(0.1)%	(0.1)%
Core revenue growth (Non-GAAP)	9.1 %	3.1 %	7.2 %
Contribution to core growth:			
Price	2.1 %	2.8 %	2.3 %
Volume	7.0 %	0.3 %	4.9 %

	Three Months Ended								
	Intelligent Operating Solutions			Advanced Healthcare Solutions			Total Fortive		
	October 2, 2026	September 26, 2025	Change (%)	October 2, 2026	September 26, 2025	Change (%)	October 2, 2026	September 26, 2025	Change (%)
<i>\$ in millions</i>									
North America	\$ 483.2	\$ 433.2	11.5 %	\$ 194.9	\$ 191.5	1.8 %	\$ 678.1	\$ 624.7	8.5 %
Asia-Pacific	117.8	111.4	5.7 %	74.8	70.0	6.9 %	192.6	181.4	6.2 %
Europe, Middle East, and Africa	135.1	126.3	7.0 %	41.6	41.6	— %	176.7	167.9	5.2 %
Latin America	31.0	27.9	11.1 %	29.1	25.2	15.5 %	60.1	53.1	13.2 %
Total Revenue (GAAP)	767.1	698.8	9.8 %	340.4	328.3	3.7 %	1,107.5	1,027.1	7.8 %

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN

\$ in millions

	Three Months Ended October 2, 2026			Three Months Ended September 26, 2025		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 767.1	\$ 340.4	\$ 1,107.5	\$ 698.8	\$ 328.3	\$ 1,027.1
Gross Profit (GAAP)	\$ 514.2	\$ 196.4	\$ 710.6	\$ 457.5	\$ 191.7	\$ 649.2
Adjustments						
Discrete Restructuring Charges	—	—	—	1.4	—	1.4
IEEPA tariff refunds	(17.3)	(0.7)	(18.0)	—	—	—
Total Adjustments (Non-GAAP)	\$ (17.3)	\$ (0.7)	\$ (18.0)	\$ 1.4	\$ —	\$ 1.4
Adjusted Gross Profit (Non-GAAP)	\$ 496.9	\$ 195.7	\$ 692.6	\$ 458.9	\$ 191.7	\$ 650.6
Gross Profit Margin (GAAP)	67.0 %	57.7 %	64.2 %	65.5 %	58.4 %	63.2 %
Adjusted Gross Profit Margin (Non-GAAP)	64.8 %	57.5 %	62.5 %	65.7 %	58.4 %	63.3 %

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN FROM CONTINUING OPERATIONS

\$ in millions	Three Months Ended				
	October 2, 2026	July 3, 2026	April 3, 2026	December 31, 2025	September 26, 2025
Revenue (GAAP)	\$ 1,107.5	\$ 1,096.8	\$ 1,069.4	\$ 1,122.5	\$ 1,027.1
Net Earnings from Continuing Operations (GAAP)	\$ 172.5	\$ 157.3	\$ 136.4	\$ 191.5	\$ 117.0
Interest expense, net	38.8	35.4	31.6	31.0	25.4
Income taxes	29.8	22.2	27.2	2.4	18.0
Depreciation	22.6	22.0	20.4	18.1	17.6
Amortization	89.3	91.5	93.2	93.2	91.5
EBITDA (Non-GAAP)	353.0	328.4	308.8	336.2	269.5
Pretax acquisition, divestiture, and Separation related items ^(a)	1.0	1.4	1.9	2.1	38.3
Pretax discrete restructuring charges	1.5	2.4	6.3	18.5	2.1
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	(4.9)	(4.6)	(3.3)	1.2	(0.5)
Pretax IEEPA tariff refunds	(18.0)	(4.5)	—	—	—
Pretax capitalized software impairment	6.2	—	—	—	—
Pretax gain from divestiture	—	—	—	(0.1)	—
Adjusted EBITDA (Non-GAAP)	\$ 338.8	\$ 323.1	\$ 313.7	\$ 357.9	\$ 309.4
Trailing Twelve Months Adjusted EBITDA (Non-GAAP) as of October 2, 2026	\$ 1,333.5				
Net Earnings Margin from Continuing Operations (GAAP)	15.6 %	14.3 %	12.8 %	17.1 %	11.4 %
Adjusted EBITDA Margin (Non-GAAP)	30.6 %	29.5 %	29.3 %	31.9 %	30.1 %

(a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Net earnings from continuing operations.

The sum of the components of adjusted EBITDA may not equal due to rounding.

OPERATING PROFIT & OPERATING PROFIT MARGIN TO ADJUSTED EBITDA AND ADJUSTED MARGIN BRIDGE

\$ in millions	Three Months Ended	
	October 2, 2026	September 26, 2025
Revenue (GAAP)	\$ 1,107.5	\$ 1,027.1
Operating Profit (GAAP)	\$ 235.9	\$ 159.6
Amortization of acquisition-related intangible assets	89.3	91.5
Acquisition, divestiture, and Separation related items ^(a)	1.0	38.3
Discrete restructuring charges	1.5	2.1
IEEPA tariff refunds	(18.0)	—
Capitalized software impairment	6.2	—
Adjusted Operating Profit (Non-GAAP)	315.9	291.5
Depreciation	22.6	17.6
Other	0.3	0.3
Adjusted EBITDA (Non-GAAP)	\$ 338.8	\$ 309.4
Operating Profit Margin (GAAP)	21.3 %	15.5 %
Adjusted Operating Profit Margin (Non-GAAP)	28.5 %	28.4 %
Adjusted EBITDA Margin (Non-GAAP)	30.6 %	30.1 %

(a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs.

The sum of the components of adjusted operating profit may not equal due to rounding.

SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN

\$ in millions

	Three Months Ended October 2, 2026				Three Months Ended September 26, 2025			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Unallocated Corporate Costs & Other	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Unallocated Corporate Costs & Other	Total Fortive
Revenue (GAAP)	\$ 767.1	\$ 340.4	\$ —	\$ 1,107.5	\$ 698.8	\$ 328.3	\$ —	\$ 1,027.1
Operating Profit (GAAP)	\$ 223.4	\$ 38.2	\$ (25.7)	\$ 235.9	\$ 180.7	\$ 42.5	\$ (63.6)	\$ 159.6
Adjustments								
Amortization of acquisition-related intangible assets	44.7	44.6	—	89.3	46.4	45.1	—	91.5
Acquisition, divestiture, and Separation related items ^(a)	0.4	0.2	0.4	1.0	0.1	0.1	38.1	38.3
Discrete restructuring charges	0.7	—	0.8	1.5	2.0	0.1	—	2.1
IEEPA tariff refunds	(17.3)	(0.7)	—	(18.0)	—	—	—	—
Capitalized software impairment	6.2	—	—	6.2	—	—	—	—
Total Adjustments (Non-GAAP)	34.7	44.1	1.2	80.0	48.5	45.3	38.1	131.9
Adjusted Operating Profit (Non-GAAP)	258.1	82.3	(24.5)	315.9	229.2	87.8	(25.6)	291.5
Depreciation	16.6	5.6			\$ 12.7	\$ 4.5		
Adjusted EBITDA (Non-GAAP)	\$ 274.7	\$ 87.9			\$ 241.9	\$ 92.3		
Operating Profit Margin (GAAP)	29.1 %	11.2 %			25.9 %	12.9 %		
Adjusted Operating Profit Margin (Non-GAAP)	33.6 %	24.2 %			32.8 %	26.7 %		
Adjusted EBITDA Margin (Non-GAAP)	35.8 %	25.8 %			34.6 %	28.1 %		

(a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs.

The sum of the components of adjusted operating profit may not equal due to rounding.

ADJUSTED NET EARNINGS AND ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS

\$ in millions, except per share amounts

	Three Months Ended			
	October 2, 2026		September 26, 2025	
		Per share value		Per share value
Net Earnings and Earnings Per Share from Continuing Operations (GAAP)	\$ 172.5	\$ 0.57	\$ 117.0	\$ 0.35
Pretax amortization of acquisition related intangible assets	89.3	0.29	91.5	0.27
Pretax acquisition, divestiture, and Separation related items ^(a)	1.0	—	38.3	0.11
Pretax discrete restructuring charges	1.5	—	2.1	0.01
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	(4.9)	(0.02)	(0.5)	—
Pretax IEEPA tariff refunds	(18.0)	(0.06)	—	—
Pretax capitalized software impairment	6.2	0.02	—	—
Tax effect of the adjustments reflected above	(12.2)	(0.03)	(20.1)	(0.06)
Adjusted Net Earnings and Adjusted Earnings Per Share from Continuing Operations (Non-GAAP)	\$ 235.4	\$ 0.77	\$ 228.3	\$ 0.68
Average Common Diluted Stock Outstanding (shares in millions)		303.9		333.4

(a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Net earnings from continuing operations.

Percentages presented elsewhere may not recalculate based on the amounts shown due to rounding.

DEBT PRINCIPAL, NET DEBT, AND LEVERAGE

\$ in millions

	October 2, 2026
Current portion of long-term debt, carrying value	\$ —
Long-term debt, carrying value	3,514.2
Debt, net carrying value (GAAP)	3,514.2
Plus: Aggregate unamortized debt discounts, premiums, and issuance costs	17.8
Debt, principal amounts	3,532.0
Less: Cash and equivalents	377.3
Net debt (Non-GAAP)	\$ 3,154.7
TTM Adjusted EBITDA (Non-GAAP)	\$ 1,333.5
Gross Leverage	2.6X
Net Leverage	2.4X

FREE CASH FLOW FROM CONTINUING OPERATIONS

\$ in millions

	Three Months Ended				Trailing Twelve Months
	October 2, 2026	July 3, 2026	April 3, 2026	December 31, 2025	
Operating Cash Flows from Continuing Operations (GAAP)	\$ 313.3	\$ 298.7	\$ 220.4	\$ 344.2	\$ 1,176.6
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(29.5)	(28.1)	(26.6)	(30.4)	(114.6)
Free Cash Flow (Non-GAAP)	\$ 283.8	\$ 270.6	\$ 193.8	\$ 313.8	\$ 1,062.0
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 235.4	\$ 228.5	\$ 217.5	\$ 288.9	\$ 970.3
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	120.6 %	118.4 %	89.1 %	108.6 %	109.5 %

	Three Months Ended				Trailing Twelve Months
	September 26, 2025	June 27, 2025	March 28, 2025	December 31, 2024	
Operating Cash Flows from Continuing Operations (GAAP)	\$ 294.7	\$ 205.0	\$ 191.8	\$ 327.7	\$ 1,019.2
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(28.6)	(25.0)	(21.1)	(22.6)	(97.3)
Free Cash Flow (Non-GAAP)	\$ 266.1	\$ 180.0	\$ 170.7	\$ 305.1	\$ 921.9
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 228.3	\$ 197.8	\$ 191.1	\$ 279.8	\$ 897.0
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	116.6 %	91.0 %	89.3 %	109.0 %	102.8 %

ADJUSTED P&L

\$ in millions, except per share amounts

Three Months Ended October 2, 2026												
	Intelligent Operating Solutions			Advanced Healthcare Solutions			Unallocated Corporate Costs & Other			Total Fortive		
	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)
Revenue	\$ 767.1	\$ —	\$ 767.1	\$ 340.4	\$ —	\$ 340.4	\$ —	\$ —	\$ —	\$ 1,107.5	\$ —	\$ 1,107.5
Cost of sales	(252.9)	17.3	(270.2)	(144.0)	0.7	(144.7)	—	—	—	(396.9)	18.0	(414.9)
Gross profit	514.2	(17.3)	496.9	196.4	(0.7)	195.7	—	—	—	710.6	(18.0)	692.6
Operating expenses	(290.8)	52.0	(238.8)	(158.2)	44.8	(113.4)	(25.7)	1.2	(24.5)	(474.7)	98.0	(376.7)
Operating Profit	\$ 223.4	\$ 34.7	\$ 258.1	\$ 38.2	\$ 44.1	\$ 82.3	\$ (25.7)	\$ 1.2	\$ (24.5)	\$ 235.9	\$ 80.0	\$ 315.9
Interest expense, net										(38.8)	—	(38.8)
Other non-operating income, net										5.2	(4.9)	0.3
Earnings from continuing operations before income taxes										202.3	75.1	277.4
Income taxes										(29.8)	(12.2)	(42.0)
Net earnings from continuing operations										\$ 172.5	\$ 62.9	\$ 235.4
Average Common Diluted Stock Outstanding (shares in millions)										303.9	—	303.9
Earnings Per Share from Continuing Operations										\$ 0.57	\$ 0.20	\$ 0.77
Operating Profit	\$ 223.4	\$ 34.7	\$ 258.1	\$ 38.2	\$ 44.1	\$ 82.3	\$ (25.7)	\$ 1.2	\$ (24.5)	\$ 235.9	\$ 80.0	\$ 315.9
Depreciation	16.6	—	16.6	5.6	—	5.6	0.4	—	0.4	22.6	—	22.6
Other							0.3	—	0.3	0.3	—	0.3
Adjusted EBITDA (Non-GAAP)			\$ 274.7			\$ 87.9			\$ (23.8)			\$ 338.8

ADJUSTED P&L

\$ in millions, except per share amounts

Three Months Ended September 26, 2025												
	Intelligent Operating Solutions			Advanced Healthcare Solutions			Unallocated Corporate Costs & Other			Total Fortive		
	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)	GAAP	Adjust-ments	Adjusted (Non-GAAP)
Revenue	\$ 698.8	\$ —	\$ 698.8	\$ 328.2	\$ —	\$ 328.2	\$ —	\$ —	\$ —	\$ 1,027.0	\$ —	\$ 1,027.0
Cost of sales	(241.3)	(1.4)	(239.9)	(136.5)	0.7	(137.2)	—	—	—	(377.8)	(0.7)	(377.1)
Gross profit	457.5	1.4	458.9	191.7	(0.7)	191.0	—	—	—	649.2	0.7	649.9
Operating expenses	(276.8)	47.1	(229.7)	(149.2)	46.0	(103.2)	(63.6)	38.1	(25.5)	(489.6)	131.2	(358.4)
Operating Profit	\$ 180.7	\$ 48.5	\$ 229.2	\$ 42.5	\$ 45.3	\$ 87.8	\$ (63.6)	\$ 38.1	\$ (25.5)	\$ 159.6	\$ 131.9	\$ 291.5
Interest expense, net										(25.4)	—	(25.4)
Other non-operating income, net										0.8	(0.5)	0.3
Earnings from continuing operations before income taxes										135.0	131.4	266.4
Income taxes										(18.0)	(20.1)	(38.1)
Net earnings from continuing operations										\$ 117.0	\$ 111.3	\$ 228.3
Average Common Diluted Stock Outstanding (shares in millions)										333.4	—	333.4
Earnings Per Share from Continuing Operations										\$ 0.35	\$ 0.33	\$ 0.68
Operating Profit	\$ 180.7	\$ 48.5	\$ 229.2	\$ 42.5	\$ 45.3	\$ 87.8	\$ (63.6)	\$ 38.1	\$ (25.5)	\$ 159.6	\$ 131.9	\$ 291.5
Depreciation	12.7	—	12.7	4.5	—	4.5	0.4	—	0.4	17.6	—	17.6
Other							0.3	—	0.3	0.3	—	0.3
Adjusted EBITDA (Non-GAAP)			\$ 241.9			\$ 92.3			\$ (24.8)			\$ 309.4

